(Reuters) - Hikma Pharmaceuticals Plc has won exclusive rights to distribute and market its third biosimilar drug - a copy of Roche's blood cancer treatment Rituxanin - in the Middle East and North African markets, it said on Tuesday.
from Reuters: Health News http://ift.tt/2CCOcvd
No comments:
Post a Comment